TRIZIVIR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
TRIZIVIR by GSK is [see clinical pharmacology (12. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIZIVIR is an oral small-molecule antiviral therapy approved in 2000 for the treatment of HIV infection. It is a fixed-dose combination tablet designed to simplify patient dosing regimens. The drug represents a established treatment option in the antiretroviral landscape.
$0.001BPart D
LOE ApproachingDeclining
Minimal commercial activity with <1M in Part D spending and 618 claims in 2023 indicates a small, shrinking patient base with limited career momentum.
Mechanism of Action
[see Clinical Pharmacology (12.4)] .
Clinical Trials (7)
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
Started Aug 2006
17 enrolled
HIV
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
Started Jun 2006
730 enrolled
HIV Infections
Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults
Started Jan 2005
152 enrolled
HIV Infections
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
Started Apr 2004
Infection, Human Immunodeficiency Virus IHIV Infection
FREE Study: Efficacy and Toxicity of Trizivir
Started Mar 2003
207 enrolled
HIV Infections
Worked on TRIZIVIR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.